Cell Signaling Technology Engager | In-Person Event

_20220415_cpub_cst_logo

Thursday 13th October, 2022 | 6:00pm BST

Free-to-Attend & In-Person Only Event

Cambridge, UK - Venue TBC

De-risking Oncology Drug Discovery for Targeted Degradation

With a multitude of recent failures in the clinic, it is more important than ever to ensure that you have the highest confidence in your TPD and RNAi candidates before bringing it to trial.

This Cell Signaling Technology Engager has been specifically designed to provide Biopharma Scientists, Directors and Heads of Departments working in the TPD and RNAi field within pre-clinical development departments with the opportunity to discuss the challenges and best practices when it comes to antibody selection to successfully move TPD and RNAi candidates into the clinic.

This in person learning and networking Engager will allow attendees to hear from lead experts in drug and assay development about the importance of antibody targets, efficacy and safety before entering clinical trials, as well as guiding you in the right direction of reagent selection and assay development and providing you with technical support and methods to accelerate your TPD or RNAi candidate down the pipeline.

Join us for an insightful panel discussion among pharma and research key opinion leaders, followed by some appetizers and drinks!

Please Note: This event is taking place in-person only (Cambridge, UK) and online attendance will not be available.

Expert Speakers Include:

Sam Jensen

Global Strategic Marketing Manager, BioPharma

Cell Signaling Technology

Roberto Polakiewicz

Chief Scientific Officer

Cell Signaling Technology

Kathy Dodgson

Director of Biology Operations

Aurelia Bioscience

Laura Rosenberg

Director, Functional Genomics

AstraZeneca

Reserve Your Free Seat By Filling Out the Form Below:

Please Note: This event is taking place in-person only (Cambridge, UK) and online attendance will not be available.

This event is reserved for decision makers and senior representatives in the biopharma community with therapies in their pipeline. By registering online, you are submitting your interest in this exclusive networking meeting, and a colleague will be in touch upon registering to confirm or decline your place based on the mentioned criteria.

Having trouble registering? Email: info@hansonwade.com

*Attendance is subject to final approval from the event organizers

Agenda & Venue:

Clayton Hotel Cambridge

27-29 Station Road, Cambridge, CB1 2FB

United Kingdom

Clayton External

6:00 pm Registration & Welcome Reception

6:30 pm Opening Remarks & Introduction

  • Sam Jensen Global Strategic Marketing Manager, BioPharma, Cell Signaling Technology

6:40 pm Interactive Panel Discussion & Q&A: De-risking Oncology Drug Discovery for Targeted Degradation

Synopsis

  • Review how assay development and reagent selection can influence go- and no-go decisions prior to advancing a TPD or RNAi candidate into the clinic
  • Discuss the challenges, strategies and best practices when it comes to confident results interpretation of efficacy and safety of drug candidates

More speakers TBC!

7:15 pm Networking & Drinks

Synopsis

This is an informal and exclusive networking opportunity for you to engage with biopharma leaders and Cell Signaling Technology to discuss how to successfully move your TPD or RNAi candidates to the clinic

8:00 pm Closing Remarks & End of Cell Signaling Technology Engager

About Cell Signaling Technology:

_20220415_cpub_cst_logo

Put our experience to work for you: Cell Signaling Technology (CST) scientists are biology, application, and therapeutic area domain experts and are here to streamline your discovery. We are passionate about science and keep up with all the latest research and new treatment approaches in oncology therapeutic areas, allowing us to offer a broad antibody portfolio against targets that could lead to new, more efficacious therapies.